SCTbio and CCRM Nordic Form Strategic Partnership to Accelerate Advanced Therapy Development

CCRM Nordic today entered into a strategic partnership with Czech CDMO SCTbio to accelerate ATMP development and manufacturing. Learn more by reading the press release: https://www.thepharmaletter.com/sctbio-and-ccrm-nordic-ink-partnership-on-atmps 

Contacts 

Fredrik Wessberg, fredrik.wessberg@ccrmnordic.se 

About CCRM Nordic: 

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs. 

About CCRM: 

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca 

About SCTbio 

SCTbio is a leading Contract Development and Manufacturing Organization (CDMO) specializing in Advanced Therapy Medicinal Products. With a decade of experience in cell therapy manufacturing, SCTbio provides comprehensive GMP production services including genetic modification, viral vectors, and autologous cell-based products. The company offers end-to-end support spanning process development, manufacturing, quality control, QA/QP release, storage, and logistics. As a strategic manufacturing partner, SCTbio guides clients through every stage of the cell therapy development journey, ensuring the highest quality standards for clinical trials and commercial production. 

SCTbio is a member of PPF Biotech group. To learn more, visit www.sctbio.com.